US-based Aveo Pharmaceuticals and Swiss drugmaker Novartis have scrapped their $326m worth licensing agreement to develop and commercialize the former’s humanized inhibitory antibody AV-380 and other related antibodies.
TRIGR Therapeutics and ABL Bio have entered into a binding agreement for TRIGR to license the global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer.
Private equity firm CVC Capital Partners-led consortium has agreed to acquire controlling stake in Italian drugmaker, Recordati, in a deal valued at €3.03bn.
The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new therapies for heart failure.
Biogen has agreed to increase its stake in biopharmaceutical company Samsung Bioepis to nearly 49.9% in a deal of about $700m with its joint venture (JV) partner Samsung BioLogics.
LUMICKS has partnered with AstraZeneca and the University of Cambridge Biochemistry Department to form the Center of Excellence for Dynamic Single-Molecule Analysis for accelerated drug discovery and biology.
Biopharmaceutical firm AbbVie and Calibr, the drug discovery division of Scripps Research, have entered into a collaboration to develop T-cell therapies aimed mainly at cancer, including solid tumors.
The Dementia Discovery Fund (DDF) has announced the completion of its fundraising, with £250m ($350m at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia.
Erytech Pharma has announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications.
Ironwood Pharmaceuticals has initiated two Phase III clinical trials to assess the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.